(TOI) The Oncology Institute, Inc. ANSOFF Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TOI) The Oncology Institute, Inc. Complete Analysis Pack
Unlock the Full Ansoff Matrix for Deeper Strategic Insight
This The Oncology Institute, Inc. Ansoff Matrix Analysis maps the company’s growth options across market penetration, market development, product development, and diversification, showing practical strategic moves you can use for research, investing, or planning. The page includes a real preview/sample of the analysis so you can judge style and substance before buying; purchase the full version to receive the complete ready-to-use report.
Market Penetration
67-clinic footprint
The Oncology Institute, Inc. has a 67-clinic footprint, which gives it a direct base to grow share in the same local markets. Market penetration here means more referrals, more repeat visits, and tighter continuity of care, not a new service mix. With 67 sites already in place, the clearest upside is to push higher patient volume through the existing network.
On-site infusion and dispensing
The Oncology Institute, Inc. already uses on-site infusion and medication dispensing, so it can keep more of each cancer episode inside its own network. That cuts leakage to outside providers and supports more visits per patient in current markets. Site-of-care shifts also matter financially: outpatient infusion is often paid at a lower cost than hospital-based care, while TOI keeps both administration and dispensing revenue in-house.
Clinical-trial enrollment
TOI actively manages clinical trials, so this market-penetration play can keep more patients in its care path and make the practice stand out in existing markets. More trial participation also helps use physician time, infusion chairs, and clinic space more fully. In 2025/2026, this matters because trial-driven volume can raise retention without adding new locations.
Radiation and medical oncology coordination
TOI’s radiation therapy and direct physician care sit in one care path, so more patients can stay inside the same network for both consults and treatment. That setup can lift capture from existing patients and drive more internal referrals across TOI’s footprint.
- One-stop care boosts patient retention.
- Internal referrals increase treatment share.
- Shared care plans improve conversion.
Palliative and support-service retention
TOI’s palliative care and patient support services fit Market Penetration because they keep adult and senior cancer patients engaged through long treatment cycles. In FY2025, that kind of continuity matters most where repeat visits, care coordination, and symptom control drive stickiness in current markets. Better support can lift retention, reduce drop-offs, and protect visit volume without needing new geographies.
- Improves continuity across long care cycles
- Supports retention in current markets
- Raises patient stickiness through care coordination
TOI Can Grow by Deepening Share Across Its 67-Clinic Footprint
The Oncology Institute, Inc. can still grow inside its own map: 67 clinics, in-house infusion, dispensing, trials, radiation, and palliative care all support more visits, less leakage, and stronger retention in FY2025/2026. This is market penetration, not expansion into new care lines.
| Metric | FY2025/2026 data | Penetration effect |
|---|---|---|
| Clinic footprint | 67 clinics | More local share |
| Care model | Infusion, dispensing, trials | More in-network volume |
| Service mix | Radiation, palliative care | Higher retention |
What is included in the product
Detailed Word Document
Analyzes The Oncology Institute, Inc.’s growth strategy through the four core directions of the Ansoff Matrix
Editable Excel File
Provides a quick Ansoff Matrix view for The Oncology Institute, Inc. to simplify growth strategy decisions across markets and services.
Reference Sources
Consolidates primary, peer-reviewed, regulatory, and company sources to validate Ansoff Matrix growth paths for The Oncology Institute, Inc., enabling fast, traceable due diligence.
Market Development
Replicate the clinic model
The Oncology Institute, Inc. can use its multi-site oncology clinic model to enter more U.S. markets without changing the core format. Its 67-site network already shows the model scales across geographies, so market development here means opening similar clinics in new cities and states while reusing the same care, staffing, and operating playbook.
New metro-area entry
The Oncology Institute, Inc., based in Cerritos, California, already treats patients across the United States, so it can move into new metro areas without changing its core oncology model. That makes market development low-friction: same services, new local demand, and faster scaling through existing care workflows. With 2025 U.S. cancer incidence still near 2 million new cases a year, metro expansion keeps the company close to large patient pools.
Outpatient infusion expansion
The Oncology Institute, Inc. already has integrated infusion in its platform, so opening new clinics with the same capability is a clear market-development move. It extends an existing service into new geographies, which can capture more oncology patients without changing the core offer. Site-of-care shifts matter too: outpatient infusion can cost 35% to 65% less than hospital outpatient settings.
Clinical-trial site expansion
TOI already runs clinical trials, so moving that capability into new markets is a low-risk market development play. It can pull in patients and referring doctors where TOI has no local brand yet, while using the same trial operations and oncology expertise. The global oncology clinical-trial market was about $12 billion in 2025, showing real demand for site growth.
- Uses an existing strength in new geographies
- Can lift patient and physician referrals
- Taps a large 2025 oncology trial market
Adult and senior cancer access
The Oncology Institute, Inc. serves mostly adult and senior cancer patients, a group that makes up most U.S. cancer incidence; the American Cancer Society projects about 2.0 million new cases in 2026. Extending the same care model into nearby service lines, like advanced diagnostics or infusion sites, widens reach without changing the core patient base.
- Adult and senior focus stays unchanged
- New service areas can lift local access
- Scale comes from care expansion, not segment shift
TOI’s 67-Site Model Poised to Expand into New U.S. Cancer Markets
The Oncology Institute, Inc. can expand its 67-site oncology model into new U.S. metros with little change to its core care playbook. That is classic market development: same services, new geography. In 2026, U.S. cancer cases are projected at about 2.0 million, keeping new-city expansion tied to large patient pools.
| Metric | Value |
|---|---|
| Sites | 67 |
| 2026 U.S. new cancer cases | ~2.0M |
| Move | New geographies |
Preview the Actual Deliverable
The Oncology Institute, Inc. Reference Sources
This is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.
Product Development
More clinical-trial protocols
TOI already runs clinical trials, so adding more protocols would deepen its offer in the same markets. With only about 5% of U.S. adult cancer patients enrolled in trials, more options can help TOI capture unmet demand and keep care in-house. That can raise visit volume, improve retention, and give patients more treatment paths without leaving the network.
Broader stem-cell programs
Broader stem-cell programs fit product development: The Oncology Institute, Inc. can deepen outpatient transplants and transfusions, so more complex care stays inside its clinic network. The American Cancer Society projects about 2.0 million new U.S. cancer cases in 2026, which supports demand for specialty oncology services. This can lift visit mix and keep patients in-house longer.
Expanded radiation services
TOI already offers radiation therapy, so expanding this service line fits product development, not new-market entry. In 2025, that means deeper care for the same patient base, with more treatment steps kept inside Company Name’s oncology stack. It can lift revenue per patient and strengthen retention without opening a new geography.
Deeper palliative care
TOI already runs palliative care, so product development here means adding more symptom control and tighter care coordination for the same patient base. That deepens the oncology care bundle and can lift retention without chasing a new market.
- More symptom support
- Better care coordination
- Same-market expansion
Enhanced patient support
The Oncology Institute, Inc. can treat enhanced patient support as product development because it adds a new layer of value to its existing care model: better navigation, stronger adherence, and tighter follow-up. That matters in oncology, where missed visits and treatment gaps can quickly hurt outcomes and raise avoidable cost.
- Builds on current support services
- Improves patient navigation
- Raises adherence and follow-up
- Adds value without new geography
Product Expansion to Capture More Oncology Patients
Product development for The Oncology Institute, Inc. means adding more trial protocols, stem-cell support, radiation, and palliative tools to the same patient base. U.S. adult cancer trial enrollment is still about 5%, so new options can keep care in-network and raise retention. The American Cancer Society projects about 2.0 million new U.S. cancer cases in 2026, supporting demand for deeper oncology services.
| Data point | Value |
|---|---|
| U.S. adult trial enrollment | ~5% |
| New U.S. cancer cases, 2026 | ~2.0 million |
| Product development effect | Higher retention |
Diversification
Care-adjacent service expansion
For The Oncology Institute, Inc., diversification means moving beyond oncology clinic visits into a new service line such as care navigation, survivorship support, or chronic-disease case management. That is a real shift in market and capability, not just adding clinics or more cancer therapies; TOI’s 2024 filing still showed a business built around oncology care delivery, so this would be a new revenue lane.
Digital care layer
The Oncology Institute, Inc. is still clinic-led, so a digital care layer would move it into a new delivery market beyond office visits and add a new service format through virtual follow-up and remote triage. That matters in a 2025 U.S. cancer market with 2,041,910 expected new cases, because digital access can reach patients who live far from a TOI clinic. It also supports higher retention and lower visit friction.
Payer-facing oncology programs
The Oncology Institute, Inc. would be moving into diversification if it launched payer-facing oncology programs, because its buyer base would shift from patients to health plans and employers. The offer would also change from direct care delivery to oncology management services, which adds a new revenue model and new sales cycle. That matters in FY2025 because payers still face high cancer-cost pressure and want care coordination, site-of-care control, and better utilization.
Home-based support model
The Oncology Institute, Inc. is built around clinic-based oncology care, so a home-based support model would serve a new setting and need a new delivery format. That makes it diversification in the Ansoff Matrix, not market penetration or product development. Home visits, remote symptom checks, and at-home navigation could expand reach, but they would also add staffing, logistics, and compliance costs.
- Diversification: new setting + new service
- Moves care from clinic to home
- Needs new nurses, tech, and workflow
- Raises cost and execution risk
Adjacency beyond current patient segment
TOI’s core base is adult and senior cancer patients, so diversification into a new patient segment would expand both addressable demand and care mix. In 2025, U.S. cancer incidence remained concentrated in older adults, with about 60% of diagnoses in people 65+, so a move into younger or nontraditional oncology cohorts would be the clearest adjacency beyond the current model.
- Broaden patient age mix
- Expand total addressable market
- Reduce dependence on one core segment
Oncology Institute’s Diversification: Beyond the Clinic, Into New Growth
Diversification for The Oncology Institute, Inc. means adding a new business beyond clinic oncology, such as payer-facing oncology management, home-based support, or digital navigation. That is a new market and a new service line, not more of the same; in 2025, U.S. cancer cases are expected to hit 2,041,910, so reach beyond clinic walls can widen access and revenue.
| Move | Why it is diversification | 2025 data point |
|---|---|---|
| Payer programs | New buyer and revenue model | 2,041,910 cases |
| Home support | New setting and delivery | Older adults drive most cases |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.